B

BrainChild Bio

BrainChild Bio is a biotech company developing CAR T therapies for pediatric central nervous system cancers. Their lead asset, BCB-276, targets diffuse intrinsic pontine glioma (DIPG), a rare and fatal brain tumor. This Series A funding will advance clinical trials for BCB-276 and preclinical development of BCB-214.

Total raised
Undisclosed
tracked to date
Latest round
Series A
Sep 8, 2026
Known investors
3
led by undisclosed private family fund and foundation
Press coverage
2
outlets tracked

Is this your company?

Claim this profile to get matched with investors who fund Health startups in United States.

Claim this profile →

🏆 Featured in Datapile’s Q3 2026 USA Funding Report

Read the Q3 2026 USA report →
Add this badge to your site
<a href="https://datapile.co/reports/q3-2026-usa-startup-funding" target="_blank" rel="noopener" style="display:inline-flex;align-items:center;gap:8px;padding:9px 16px;border-radius:9999px;background:#0B1224;color:#ffffff;font:600 13px/1.2 -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Arial,sans-serif;text-decoration:none;border:1px solid #7C5CFF"><span style="display:inline-block;width:11px;height:11px;border-radius:3px;background:#7C5CFF"></span>Featured in Datapile&rsquo;s Q3 2026 USA Funding Report</a>

Funding history

  1. 1
    $116M series ASeries ASep 8, 2026

    Led by undisclosed private family fund and foundation

    Announcement ↗

Investors in BrainChild Bio

Backers from this company's tracked funding rounds.

  • Uundisclosed private family fund and foundationLead investorVC firm
  • SSeattle Children’s HospitalVC firm
  • WWRF CapitalVC firm

BrainChild Bio in the news

Coverage of this company's funding, tracked by Datapile.

More Health companies

Recently funded startups in the same category.

Related on Datapile